Mikhail Blagosklonny is an Oncology professor working with Roswell Park Cancer Institute. He is a professional oncologist. Mikhail is a scientist who researches about issues concerning aging and cancer. Mikhail studies targeted cancer therapies and bio gerontology in order to come up with possible treatment and prevention drugs for cancer and life longevity. Mikhail is driven by the dream of having a cancer-free society and anti-aging drugs so as to slow the process of aging. Mikhail Blagosklonny formulated the hypothesis regarding the role that TOR signaling plays in cancer and aging. He also proposed the use of Rapamycin which is a popular drug for cancer.
Mikhail Blagosklonny has a Master’s degree in Internal Medicine that he earned from the First Pavlov State Medical University. He also received his Ph.D. in Cardiology and Experimental Medicine at the First Pavlov State Medical University. Mikhail served as the associate professor at the New York Medical College in Valhalla, New York in 2002. He left this position in 2009 and went on to serve at the Roswell Park Cancer Institute. Mikhail has worked in the medical sector for many years. He has acquired extensive skills and experience. Mikhail has earned a reputation as one of the most skilled and experienced scientists in the field of oncology.
Mikhail Blagosklonny is a scientific author. He is involved with various scientific journals. He is the current chief editor at Oncotarget, Cell Cycle, and Aging. Mikhail is part of Cell Death & Differentiation where he serves on the editorial board. He gives his contributions in matters regarding aging, cancer, and oncology in general. He has more than 300 published articles and more than 25,000 citations under his name. Mikhail mostly does research on Mitosis, cancer cell cycling, cell cycle, tumor suppressors, ontogenesis, anticancer therapies, apoptosis, and anticancer therapeutics. He is the founding editor of Cell Cycle and co-founder of Oncoscience.
Mikhail encourages young scientists who wish to venture into the field of oncology to do so. He serves as a mentor and welcomes articles from other scientists to be published in his journals. Mikhail attributes his success as an oncologist to hard work, passion, and discipline. Follow Mikhail on Google Scholar